BCL6 Promotes a Stem-Like CD8⁺ T Cell Program in Cancer via Antagonizing BLIMP1

Investigators showed that Bcl6 deficiency reduced the persistence of intratumor stem/progenitor-like CD8+ T cell cells, without affecting their generation, thus abrogating long-term tumor control.